AAM
REGN icon

American Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

American Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-35
Closed -$16K – 68
2015
Q3 		$16K Buy
+35
New +$18.8K 0.01% 69
2014
Q4 		– Sell
-35
Closed -$13K – 66
2014
Q3 		$13K Buy
+35
New +$11.7K 0.01% 63

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

American Asset Management's REGN Position: Q4 2015 in Review

American Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2015, closing a stake of 35 shares — an estimated $16K sold.

American Asset Management first reported a position in REGN in Q3 2014 and held it in 2 quarters. The position peaked at $16K in Q3 2015. 577 funds tracked by Wall St. Rank hold REGN as of Q4 2015.

  • American Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • American Asset Management sold 35 Regeneron Pharmaceuticals shares in Q4 2015, an estimated $16K.
  • American Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • American Asset Management's Regeneron Pharmaceuticals position peaked at $16K in Q3 2015.
  • 577 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2015.

Based on American Asset Management's 13F filing for Q4 2015, filed 19 Jan 2016.